MedTrace Logo

Clinical Study of Previously Untreated Patients With Malignant Melanoma

NCT00232726 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2007-07-10

No results posted yet for this study

Summary

Previously untreated patients with malignant melanoma receive a new chemotherapy drug currently under development. CP-4055 is given intravenously on days 1-5 every four weeks until complete response or disease progression.

Conditions

  • Malignant Melanoma
  • Neoplasm Metastasis

Interventions

DRUG

CP-4055 (ELACYT)

Sponsors & Collaborators

  • Clavis Pharma

    lead INDUSTRY

Principal Investigators

  • Svein Dueland, MD, Ph.D · The Norwegian Radium Hospital, Montebello, NO-0310 Oslo, Norway

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2007-07-31

Countries

  • United States
  • Norway
  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00232726 on ClinicalTrials.gov